Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Phone+1-847-9081604
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Sagent Pharmaceuticals (NASDAQ:SGNT) Frequently Asked Questions
What is Sagent Pharmaceuticals' stock symbol?
Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."
How were Sagent Pharmaceuticals' earnings last quarter?
Sagent Pharmaceuticals Inc (NASDAQ:SGNT) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.01) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.05 by $0.06. The firm earned $77.30 million during the quarter, compared to analysts' expectations of $83.28 million. Sagent Pharmaceuticals's revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.09 EPS. View Sagent Pharmaceuticals' Earnings History.
Has Sagent Pharmaceuticals been receiving favorable news coverage?
News coverage about SGNT stock has trended negative on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sagent Pharmaceuticals earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
What other stocks do shareholders of Sagent Pharmaceuticals own?
How do I buy shares of Sagent Pharmaceuticals?
Shares of SGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sagent Pharmaceuticals' stock price today?
One share of SGNT stock can currently be purchased for approximately $21.76.
What is Sagent Pharmaceuticals' official website?
How can I contact Sagent Pharmaceuticals?
Sagent Pharmaceuticals' mailing address is 1901 N Roselle Rd Ste 700, SCHAUMBURG, IL 60195-3194, United States. The company can be reached via phone at +1-847-9081604.
MarketBeat Community Rating for Sagent Pharmaceuticals (NASDAQ SGNT)
MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
